Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) Other Operating Expenses (2021 - 2024)

Historic Other Operating Expenses for GeneDx Holdings (WGS) over the last 4 years, with Q4 2024 value amounting to -$785000.0.

  • GeneDx Holdings' Other Operating Expenses rose 6003.05% to -$785000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was -$785000.0, marking a year-over-year increase of 8288.27%. This contributed to the annual value of -$3.4 million for FY2024, which is 5283.12% up from last year.
  • As of Q4 2024, GeneDx Holdings' Other Operating Expenses stood at -$785000.0, which was up 6003.05% from -$774000.0 recorded in Q3 2024.
  • In the past 5 years, GeneDx Holdings' Other Operating Expenses ranged from a high of $13.0 million in Q2 2021 and a low of -$2.8 million during Q3 2023
  • For the 4-year period, GeneDx Holdings' Other Operating Expenses averaged around -$83374.5, with its median value being -$974000.0 (2024).
  • As far as peak fluctuations go, GeneDx Holdings' Other Operating Expenses tumbled by 6464.35% in 2023, and later surged by 7229.78% in 2024.
  • Quarter analysis of 4 years shows GeneDx Holdings' Other Operating Expenses stood at $13.0 million in 2021, then crashed by 112.3% to -$1.6 million in 2022, then dropped by 22.75% to -$2.0 million in 2023, then soared by 60.03% to -$785000.0 in 2024.
  • Its last three reported values are -$785000.0 in Q4 2024, -$774000.0 for Q3 2024, and -$874000.0 during Q2 2024.